Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis c Clear all

Conditions: Skin and Soft Tissue Infections, Hiv, Hepatitis C, Bloodstream Infection
Interventions: ASAP; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Hepatitis C
Interventions: Omega-3 Fatty Acids, Placebo comparator; Dietary Supplement · Drug
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Kansas City, Missouri

Conditions: Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease, Inflammatory Disease, Blood Coagulation Disorders, Hepatitis C, Non-Metastatic Neoplasm
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections, Hepatitis C
Interventions: highly active antiretroviral therapy (HAART); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C, Cryoglobulinemia
Interventions: Harvoni, Epclusa; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 52
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more

Conditions: Liver Cancer
Interventions: Bevacizumab, Atezolizumab, Sofosbuvir, Velpatasvir, Voxilaprevir, Ribavirin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C Virus Infection, Infection, Herpesvirus 2, Human
Interventions: Valacyclovir; Drug
Lead sponsor: G.V. (Sonny) Montgomery VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: ESRD
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Chronic
Interventions: RO5024048, Ribavirin [Copegus], peginterferon alfa-2a [Pegasys]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 19
States / cities: La Jolla, California • Bradenton, Florida • Atlanta, Georgia + 14 more

Conditions: HCV Negative Status, HCV Risk Behavior
Interventions: Behavior Therapy; Behavioral
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
Interventions: SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Rochester, Minnesota + 1 more

Conditions: Chronic Hepatitis C
Interventions: statin; Drug
Lead sponsor: Bader, Ted, M.D.; Individual
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Chronic Hepatitis C
Interventions: BMS-650032, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Anaheim, California • Orlando, Florida • Baltimore, Maryland + 1 more

Conditions: Depression
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Long Beach, California • Minneapolis, Minnesota • Portland, Oregon

Conditions: Hepatitis C, Substance Use Disorders
Interventions: HCV GET-Up (Group Evaluation and Treatment Uptake); Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Chronic Hepatitis C
Interventions: NM283 plus Peg-IFNα-2a; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Atlanta, Georgia • Fairfax, Virginia

Conditions: Hepatitis C
Interventions: LADR Treatment; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 5 more

Conditions: Hepatitis C Patients
Interventions: Not listed
Lead sponsor: The Center for Rheumatic Disease, Allergy, & Immunology; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: HIV Infections, Hepatitis C
Interventions: Ribavirin, Aldesleukin, Peginterferon alfa-2b; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more

Conditions: Liver Disease
Interventions: sofosbuvir/ledipasvir, sofosbuvir, Ribavirin; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: New York, New York • Dallas, Texas

Conditions: Hepatitis C, Chronic
Interventions: Sofosbuvir, GS-0938, RBV, Placebo to match sofosbuvir, Placebo to match GS-0938; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 42
States / cities: Montgomery, Alabama • Bakersfield, California • Coronado, California + 33 more

Conditions: Hepatitis C, Infection Transmission, Maternal-Fetal
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hepatitis C, Chronic
Interventions: BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV), Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 18
States / cities: North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more

Search by objective public record fields.

ASAP: Access to Syringes at Pharmacies for the Prevention of Bloodborne Infections Among People Who Inject Drugs

Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C

A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

A Trial to Reduce Hepatitis C Among Injection Drug Users - 1

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Genetic and Biochemical Markers of Interferon-Induced Depression.

HCV Group Evaluation and Treatment Uptake (HCV GET-UP) Intervention

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation

Immune Dysregulation in Hepatitis C Patients With or Without Arthritis

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection

The Pathogenesis of Hepatitis C Virus Vertical Transmission

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)